招银国际:降和黄医药(00013.HK)目标价至31.39港元 维持“买入”评级

智通财经
Yesterday
【招银国际:降和黄医药(00013.HK)目标价至31.39港元 维持“买入”评级】智通财经APP获悉,招银国际发布研报称,由于和黄医药(00013.HK)2025年上半年业绩不及预期,以及公司下调全年指引,该行将该股目标价从34.03港元下调8%至31.39港元,维持“买入”评级。该行称,和黄医药2025年上半年业绩不及预期,全年指引下调。上半年肿瘤业务收入为1.44亿美元,同比下降15%,仅完成该行此前全年预测的36%。业绩不及预期主要由于内地市场关键产品收入下滑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10